Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Pujade-Lauraine, É., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A. M., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,893

XRCC3 promotes homology-directed repair of DNA damage in mammalian cellsPreprint

Pierce, A. J., Johnson, R. D., Thompson, L. H., & Jasin, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2633 · Cited by 1,384

Combenefit: an interactive platform for the analysis and visualization of drug combinations

Veroli, G. Y. D., Fornari, C., Wang, D. Y. Q., Mollard, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw230 · Cited by 762

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 720

Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation

Chen, J., Martin, B. L., & Brautigan, D. L. (1992) · Science · doi:10.1126/science.1325671 · Cited by 601

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Liu, J. F., Barry, W. T., Birrer, M. J., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B. J., Buss, M. K., Nattam, S. R., Hurteau, J. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 592

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

Sulkowski, P. L., Corso, C. D., Robinson, N. D., Scanlon, S. E., Purshouse, K. R., Bai, H., Liu, Y., Sundaram, R. K., Hegan, D. C., Fons, N. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2463 · Cited by 575

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Clarke, N. W., Wiechno, P., Alekseev, B. Y., Sala, N., Jones, R., Kocák, I., Chiurì, V. E., Jassem, J., Fléchon, A., Redfern, C. H., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30365-6 · Cited by 405

Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition

Krawczyk, P. M., Eppink, B., Essers, J., Stap, J., Rodermond, H. M., Odijk, H., Zelensky, A. N., Chris van, B. R. E. E., Stalpers, L. J. A., Buist, M. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101053108 · Cited by 363

Hypoxia-Induced Down-regulation of BRCA1 Expression by E2Fs

Bindra, R. S., Gibson, S. L., Meng, A. X., Westermark, U., Jasin, M., Pierce, A. J., Bristow, R. G., Classon, M. K., & Glazer, P. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2119 · Cited by 346

Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2 -Mutated Ovarian Carcinoma

Sakai, W., Swisher, E. M., Jacquemont, C. F., Chandramohan, K. V., Couch, F. J., Langdon, S. P., Wurz, K., Higgins, J., Villegas, E., & Taniguchi, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1178 · Cited by 329

Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance

Chan, N. H. L., Koritzinsky, M., Zhao, H. W., Bindra, R. S., Glazer, P. M., Powell, S. N., Belmaaza, A., Wouters, B. G., & Bristow, R. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5472 · Cited by 328

Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

Li, L., Karanika, S., Yang, G., Wang, J., Park, S., Broom, B. M., Manyam, G. C., Wu, W., Luo, Y., Basourakos, S. P., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aam7479 · Cited by 297

Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment

Chan, N. H. L., Pires, I. M., Bencokova, Z., Coackley, C. L., Luoto, K. R., Bhogal, N., Lakshman, M., Gottipati, P., Oliver, F. J., Helleday, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2352 · Cited by 250

Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130

Hegan, D. C., Lü, Y., Stachelek, G. C., Crosby, M. E., Bindra, R. S., & Glazer, P. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904783107 · Cited by 211

Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia

Bindra, R. R., & Glazer, P. M. (2006) · Oncogene · doi:10.1038/sj.onc.1210001 · Cited by 167

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.

Liu, J. F., Barry, W., Birrer, M., Lee, J., Buckanovich, R. J., Fleming, G., Rimel, B., Buss, M., Nattam, S., Hurteau, J. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz018 · Cited by 165

Autophosphorylation-activated protein kinase phosphorylates and inactivates protein phosphatase 2A.

Guo, H., & Damuni, Z. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2500 · Cited by 161

Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter

Lü, Y., Chu, A., Turker, M. S., & Glazer, P. M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01121-10 · Cited by 138

Oxidative Stress Induces Protein Phosphatase 2A-dependent Dephosphorylation of the Pocket Proteins pRb, p107, and p130

Cicchillitti, L., Fasanaro, P., Biglioli, P., Capogrossi, M. C., & Martelli, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300511200 · Cited by 129

The mTOR and PP2A pathways regulate PHD2 phosphorylation to fine-tune HIF1α levels and colorectal cancer cell survival under hypoxia

Di Conza, G., Trusso Cafarello, S., Loroch, S., Mennerich, D., Deschoemaeker, S., Di Matteo, M., Ehling, M., Gevaert, K., Prenen, H., Zahedi, R. P., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.051 · Cited by 119

Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells

Bindra, R. S., Goglia, A. G., Jasin, M., & Powell, S. N. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt255 · Cited by 89

Isolation and initial characterization of the BRCA2 promoter

Davis, P. L., Miron, A., Andersen, L. M., Iglehart, J. D., & Marks, J. R. (1999) · Oncogene · doi:10.1038/sj.onc.1202990 · Cited by 60

Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay

Surovtseva, Y. V., Jairam, V., Salem, A. F., Sundaram, R. K., Bindra, R. S., & Herzon, S. B. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b00162 · Cited by 58

Hypoxic Stress Facilitates Acute Activation and Chronic Downregulation of Fanconi Anemia Proteins

Scanlon, S. E., & Glazer, P. M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0628 · Cited by 45

The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials

Guo, X. X., Wu, H., Shi, H., Su, L., & Zhang, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s169558 · Cited by 44

Protein Phosphatase 2A Associates with Rb2/p130 and Mediates Retinoic Acid-induced Growth Suppression of Ovarian Carcinoma Cells

Vuocolo, S. C., Purev, E., Zhang, D., Bártek, J., Hansen, K. H., Soprano, D. R., & Soprano, K. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302715200 · Cited by 43

Intermittent hypoxia-induced protein phosphatase 2A activation reduces PC12 cell proliferation and differentiation

Chen, T.-I., Chiu, H.-W., Pan, Y., Hsu, S.-T., Lin, J., & Yang, K. (2014) · Journal of Biomedical Science · doi:10.1186/1423-0127-21-46 · Cited by 29

Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture

Jiang, Y., Allen, P. D., Kersemans, V., Devery, A., Bokobza, S., Smart, S., & Ryan, A. J. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.009 · Cited by 15

18F-Fluoromisonidazole Kinetic Modeling for Characterization of Tumor Perfusion and Hypoxia in Response to Antiangiogenic Therapy

Grkovski, M., Emmas, S.-A., & Carlin, S. D. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.190892 · Cited by 14

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance

Wu, W. E., Klockow, J., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 877

Therapeutic targeting of the hypoxic tumour microenvironment

Singleton, D. C., Macann, A., & Wilson, W. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00539-4 · Cited by 507

Anti-angiogenic therapy: current challenges and future perspectives

Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416

Glioblastoma Therapy: Past, Present and Future

Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271

Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance

Cui, C., Yang, J., Xiao, L., Liu, D., Fu, L., & Wang, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01180-y · Cited by 205

Mechanism of Cediranib–Olaparib Combo Revealed

(2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2019-064 · Cited by 1

Abstract 3718: Sensitization of human tumor cells to chemotherapy drugs by antisense downregulation of RAD51: Targeting DNA repair to induce synthetic lethality

Ferguson, P. J., Rytelewski, M., Vincent, M. D., & Koropatnick, J. D. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-3718 · Cited by 1

Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.

Kim, J. W., Radke, M. R., Hafez, N., Soliman, H. H., Fu, S., Kato, S., Lara, P. N., Vaishampayan, U. N., Razak, A. R. A., Cardin, D. B., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.8563

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors

Jdey, W., Thierry, S., Russo, C., Devun, F., Abo, M. A., Noguiez, P., Sun, J., Barillot, E., Zinovyev, A. Y., Kuperstein, I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1193 · Cited by 42

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation

Kim, J. W., Cardin, D. B., Vaishampayan, U. N., Kato, S., Grossman, S. R., Glazer, P. M., Shyr, Y., Ivy, S. P., & LoRusso, P. M. (2021) · The Oncologist · doi:10.1002/onco.13758 · Cited by 17